Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 19 of 19 entries
Sorted by: Best Match Show Resources per page
Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells.

Cancers

King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, Chen L, Chapman D, Harrison D, Yeomanson D, Curtin NJ, Tweddle DA, Bryant HE.
PMID: 34944835
Cancers (Basel). 2021 Dec 10;13(24). doi: 10.3390/cancers13246215.

Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB....

Cite
King D, Southgate HED, Roetschke S, et al. Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246215.
King, D., Southgate, H. E. D., Roetschke, S., Gravells, P., Fields, L., Watson, J. B., Chen, L., Chapman, D., Harrison, D., Yeomanson, D., Curtin, N. J., Tweddle, D. A., & Bryant, H. E. (2021). Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers, 13(24), . https://doi.org/10.3390/cancers13246215
King, David, et al. "Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246215
King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, Chen L, Chapman D, Harrison D, Yeomanson D, Curtin NJ, Tweddle DA, Bryant HE. Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers (Basel). 2021 Dec 10;13(24). doi: 10.3390/cancers13246215. PMID: 34944835.
Copy Download .nbib Format: NLM
Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis.

Stem cells international

Carr-Wilkinson J, Prathalingam N, Pal D, Moad M, Lee N, Sundaresh A, Forgham H, James P, Herbert M, Lako M, Tweddle DA.
PMID: 30515222
Stem Cells Int. 2018 Nov 01;2018:4391641. doi: 10.1155/2018/4391641. eCollection 2018.

BACKGROUND AND AIMS: Previous studies modelling human neural crest differentiation from stem cells have resulted in a low yield of sympathetic neurons. Our aim was to optimise a method for the differentiation of human embryonic stem cells (hESCs) to...

Cite
Carr-Wilkinson J, Prathalingam N, Pal D, et al. Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis. Stem Cells Int. 2018;2018:4391641doi: 10.1155/2018/4391641.
Carr-Wilkinson, J., Prathalingam, N., Pal, D., Moad, M., Lee, N., Sundaresh, A., Forgham, H., James, P., Herbert, M., Lako, M., & Tweddle, D. A. (2018). Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis. Stem cells international, 20184391641. https://doi.org/10.1155/2018/4391641
Carr-Wilkinson, Jane, et al. "Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis." Stem cells international vol. 2018 (2018): 4391641. doi: https://doi.org/10.1155/2018/4391641
Carr-Wilkinson J, Prathalingam N, Pal D, Moad M, Lee N, Sundaresh A, Forgham H, James P, Herbert M, Lako M, Tweddle DA. Differentiation of Human Embryonic Stem Cells to Sympathetic Neurons: A Potential Model for Understanding Neuroblastoma Pathogenesis. Stem Cells Int. 2018 Nov 01;2018:4391641. doi: 10.1155/2018/4391641. eCollection 2018. PMID: 30515222; PMCID: PMC6236576.
Copy Download .nbib Format: NLM
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

Oncotarget

Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Fretwell VL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR.
PMID: 29930754
Oncotarget. 2018 Jun 05;9(43):27104-27116. doi: 10.18632/oncotarget.25497. eCollection 2018 Jun 05.

Nrf2 is a transcription factor that regulates cellular stress response and irinotecan-metabolising pathways. Its aberrant activity has been reported in a number of cancers, although relatively few studies have explored a role for Nrf2 in colorectal cancer (CRC). This...

Cite
Evans JP, Winiarski BK, Sutton PA, et al. The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget. 2018;9(43):27104-27116doi: 10.18632/oncotarget.25497.
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., Pritchard, D. M., Lin, Z. X., Fretwell, V. L., Tweedle, E. M., Costello, E., Goldring, C. E., Copple, I. M., Park, B. K., Palmer, D. H., & Kitteringham, N. R. (2018). The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 9(43), 27104-27116. https://doi.org/10.18632/oncotarget.25497
Evans, Jonathan P, et al. "The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer." Oncotarget vol. 9,43 (2018): 27104-27116. doi: https://doi.org/10.18632/oncotarget.25497
Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Fretwell VL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR. The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget. 2018 Jun 05;9(43):27104-27116. doi: 10.18632/oncotarget.25497. eCollection 2018 Jun 05. PMID: 29930754; PMCID: PMC6007465.
Copy Download .nbib Format: NLM
Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells.

Cancers

King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, Chen L, Chapman D, Harrison D, Yeomanson D, Curtin NJ, Tweddle DA, Bryant HE.
PMID: 34944835
Cancers (Basel). 2021 Dec 10;13(24). doi: 10.3390/cancers13246215.

Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB....

Cite
King D, Southgate HED, Roetschke S, et al. Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246215.
King, D., Southgate, H. E. D., Roetschke, S., Gravells, P., Fields, L., Watson, J. B., Chen, L., Chapman, D., Harrison, D., Yeomanson, D., Curtin, N. J., Tweddle, D. A., & Bryant, H. E. (2021). Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers, 13(24), . https://doi.org/10.3390/cancers13246215
King, David, et al. "Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246215
King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, Chen L, Chapman D, Harrison D, Yeomanson D, Curtin NJ, Tweddle DA, Bryant HE. Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers (Basel). 2021 Dec 10;13(24). doi: 10.3390/cancers13246215. PMID: 34944835.
Copy Download .nbib Format: NLM
Diversity of the southern Africa .

ZooKeys

Bragança PHN, van Zeeventer RM, Bills R, Tweddle D, Chakona A.
PMID: 32292273
Zookeys. 2020 Apr 01;923:91-113. doi: 10.3897/zookeys.923.48420. eCollection 2020.

Through the analysis of a comprehensive database of COI sequences, with the sequencing of 48 specimens, a first insight into the genetic diversity, distribution and relationships between the southern Africa "

Cite
Bragança PHN, van Zeeventer RM, Bills R, et al. Diversity of the southern Africa . Zookeys. 2020;923:91-113doi: 10.3897/zookeys.923.48420.
Bragança, P. H. N., van Zeeventer, R. M., Bills, R., Tweddle, D., & Chakona, A. (2020). Diversity of the southern Africa . ZooKeys, 92391-113. https://doi.org/10.3897/zookeys.923.48420
Bragança, Pedro H N, et al. "Diversity of the southern Africa ." ZooKeys vol. 923 (2020): 91-113. doi: https://doi.org/10.3897/zookeys.923.48420
Bragança PHN, van Zeeventer RM, Bills R, Tweddle D, Chakona A. Diversity of the southern Africa . Zookeys. 2020 Apr 01;923:91-113. doi: 10.3897/zookeys.923.48420. eCollection 2020. PMID: 32292273; PMCID: PMC7142171.
Copy Download .nbib Format: NLM
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma.

Frontiers in oncology

Southgate HED, Chen L, Curtin NJ, Tweddle DA.
PMID: 32309213
Front Oncol. 2020 Apr 03;10:371. doi: 10.3389/fonc.2020.00371. eCollection 2020.

Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB) remains

Cite
Southgate HED, Chen L, Curtin NJ, et al. Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Front Oncol. 2020;10:371doi: 10.3389/fonc.2020.00371.
Southgate, H. E. D., Chen, L., Curtin, N. J., & Tweddle, D. A. (2020). Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in oncology, 10371. https://doi.org/10.3389/fonc.2020.00371
Southgate, Harriet E D, et al. "Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma." Frontiers in oncology vol. 10 (2020): 371. doi: https://doi.org/10.3389/fonc.2020.00371
Southgate HED, Chen L, Curtin NJ, Tweddle DA. Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Front Oncol. 2020 Apr 03;10:371. doi: 10.3389/fonc.2020.00371. eCollection 2020. PMID: 32309213; PMCID: PMC7145987.
Copy Download .nbib Format: NLM
Frequency and Prognostic Impact of .

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G.
PMID: 34115544
J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11.

PURPOSE: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied MATERIALS AND METHODS: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine RESULTS: Genomic CONCLUSION:...

Cite
Bellini A, Pötschger U, Bernard V, et al. Frequency and Prognostic Impact of . J Clin Oncol. 2021;39(30):3377-3390doi: 10.1200/JCO.21.00086.
Bellini, A., Pötschger, U., Bernard, V., Lapouble, E., Baulande, S., Ambros, P. F., Auger, N., Beiske, K., Bernkopf, M., Betts, D. R., Bhalshankar, J., Bown, N., de Preter, K., Clément, N., Combaret, V., Font de Mora, J., George, S. L., Jiménez, I., Jeison, M., Marques, B., Martinsson, T., Mazzocco, K., Morini, M., Mühlethaler-Mottet, A., Noguera, R., Pierron, G., Rossing, M., Taschner-Mandl, S., Van Roy, N., Vicha, A., Chesler, L., Balwierz, W., Castel, V., Elliott, M., Kogner, P., Laureys, G., Luksch, R., Malis, J., Popovic-Beck, M., Ash, S., Delattre, O., Valteau-Couanet, D., Tweddle, D. A., Ladenstein, R., & Schleiermacher, G. (2021). Frequency and Prognostic Impact of . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(30), 3377-3390. https://doi.org/10.1200/JCO.21.00086
Bellini, Angela, et al. "Frequency and Prognostic Impact of ." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,30 (2021): 3377-3390. doi: https://doi.org/10.1200/JCO.21.00086
Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Frequency and Prognostic Impact of . J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11. PMID: 34115544.
Copy Download .nbib Format: NLM
Showing 13 to 19 of 19 entries